The FDA has approved a new schizophrenia drug, Cobenfy, offering hope to patients with treatment-resistant symptoms. Targeting muscarinic receptors, it promises a new approach to managing the condition. Potential side effects include nausea and vomiting, with ongoing testing for other psychiatric disorders.